RECORDATI RARE DISEASES ANNOUNCES POSITIVE DATA FROM PHASE III LINC 4, PHASE III LINC 3, AND ILLUSTRATE ISTURISA® STUDIES PRESENTED AT ENDO 2022 06/15/2022 RECORDATI RARE DISEASES ANNOUNCES SEVERAL SCIENTIFIC ABSTRACTS TO BE PRESENTED AT THE UPCOMING ENDO SOCIETY ANNUAL MEETING 06/08/2022 PHASE III LINC 3 STUDY DEMONSTRATES THAT ISTURISA® (OSILODROSTAT) IMPROVES PHYSICAL FEATURES ASSOCIATED WITH HYPERCORTISOLISM IN PATIENTS WITH CUSHING’S DISEASE 05/13/2022 Pagination First page « First Previous page ‹ Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next › Last page Last »
RECORDATI RARE DISEASES ANNOUNCES POSITIVE DATA FROM PHASE III LINC 4, PHASE III LINC 3, AND ILLUSTRATE ISTURISA® STUDIES PRESENTED AT ENDO 2022 06/15/2022
RECORDATI RARE DISEASES ANNOUNCES SEVERAL SCIENTIFIC ABSTRACTS TO BE PRESENTED AT THE UPCOMING ENDO SOCIETY ANNUAL MEETING 06/08/2022
PHASE III LINC 3 STUDY DEMONSTRATES THAT ISTURISA® (OSILODROSTAT) IMPROVES PHYSICAL FEATURES ASSOCIATED WITH HYPERCORTISOLISM IN PATIENTS WITH CUSHING’S DISEASE 05/13/2022
